Compare Goldman Sachs Group Inc (GS) vs Tango Therapeutics Inc. (TNGX) Price & Performance

Goldman Sachs (GS) trades at $893.95, down 0.15% with bearish technical signals but strong fundamental performance. The stock shows consistent earnings beats with Q3 2026 EPS of $17.01 exceeding expectations by 32%. Revenue growth accelerated to $58.28B in 2025 with net income margin improving to 29.46%. Recent news highlights the company's focus on expanding its $70B revenue base and AI initiatives.

GS presents a compelling value case with a P/E of 13.77 below industry averages, supported by 40% analyst buy ratings and a $1,130 consensus price target. However, negative operating cash flow trends and bearish technical indicators suggest near-term volatility. The dividend yield of approximately 0.56% provides income support while the company executes its growth strategy.

TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.

Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.